All In Biotech

Drug Trial Radar · NCT05974774

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors; a Phase 3 Pragmatic Randomized Trial.

Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,600

Planned (sponsor's estimate)

Start

May 23, 2025

Primary completion

May 23, 2035

Study completion Jun 1, 2039

Sponsor

Sponsor type
Research network
Collaborators
Cancer Trials Ireland; UNICANCER; Spanish Oncology Genito-Urinary Group
First posted
Aug 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.

Conditions

  • Prostate Cancer

Interventions

  • iMABDrug

    no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.

  • cMABDrug

    LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. overall survivalTime frame: 10 years from randomisation
  2. proportion of patients who do not restart their hormonal therapy within 1 year of interrupting their MAB therapy (given as part of the induction phase)Time frame: 1 year from stopping the MAB therapy

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • University Hospitals Copenhagen - Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Centre Francois Baclesse

    Caen, France · Recruiting

  • Institut Daniel Hollard

    Grenoble, France · Recruiting

  • Clinique La Croix Du Sud

    Quint-Fonsegrives, France · Recruiting

  • CHU de Toulouse - Institut Claudius Regaud - IUCT oncopole

    Toulouse, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Hospital De La Santa Creu I Sant Pau

    Barcelona, Spain · Recruiting

  • Hospital Universitario San Carlos

    Madrid, Spain · Recruiting

  • Hospital Universitario Puerta De Hierro

    Majadahonda, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.